Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — Q4 2023 Earnings Presentation
13 slides from Aquestive Therapeutics's earnings presentation, Mar 5, 2024
Slide 1: Q4 2023 Earnings Supplemental Materials
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Q4 2024 Earnings Supplemental Materials March 5, 2024 1
Slide 2: Disclaimer
Advancing medicines. Solving problems. Improving lives. 2 ® Disclaimer Certain statements in this presentation include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend
Slide 3: Q4 2023 Earnings: Key Messages
Advancing medicines. Solving problems. Improving lives. 3 Q4 2023 Earnings: Key Messages Financial Performance Exceeded our revenue and Non-GAAP Adjusted EBITDA guidance $45MM debt refinancing resulted in cash savings of approximately $28MM through June of 2025 Finished the year with approxima
Slide 4: Consistent Execution in Q4
Advancing medicines. Solving problems. Improving lives. 4 Consistent Execution in Q4 Received positive FDA feedback on Anaphylm pivotal study protocol November Completed $45MM debt refinancing Presented positive data from Anaphylm pilot studies at America College of Allergy, Asthma, and Immunolo
Slide 5: Anaphylm Pivotal Study
Advancing medicines. Solving problems. Improving lives. Anaphylm Pivotal Study 5
Slide 6: Anaphylm Pivotal Study Design
Advancing medicines. Solving problems. Improving lives. Anaphylm Pivotal Study Design 6 Healthy volunteers (n=36) Anaphylm Epi Manual EpiPen® Anaphylm Epi Manual Epipen 15 min Dose #1 Repeat Dose Dose #2 Single Dose Healthy volunteers (n=64) Anaphylm Epi Manual Auvi-Q® EpiPen
Slide 7: Key Endpoints
Advancing medicines. Solving problems. Improving lives. Key Endpoints 7 Pharmacokinetic (PK) Pharmacodynamic (PD) • Maximum plasma concentration (Cmax) • Time to maximum plasma concentration (Tmax) • Partial area under the curve at 10, 20, 30, and 45 minutes • Change in systolic blood pressure • Cha
Slide 8: Financial Results
Advancing medicines. Solving problems. Improving lives. Financial Results 8
Slide 9: Continuing to Manage Our Cash Position
Advancing medicines. Solving problems. Improving lives. 9 Continuing to Manage Our Cash Position1 26.9 22.4 24.9 23.9 0 5 10 15 20 25 30 Ending Cash C as h in M ill io ns Ending Cash by Quarter Q1 2023 Q2 2023 Q3 2023 Q4 2023 1.Principal and interest debt payments were made on October 2, 2023, when
Slide 10: Our Base Business Excluding R&D Expenses
Advancing medicines. Solving problems. Improving lives. 10 Our Base Business Excluding R&D Expenses1 1. Non-GAAP adjusted EBITDA excluding research and development expenses -8.9 -18.6 1.0 -20 -15 -10 -5 0 5 U S D ol la rs in M ill io ns Year Base Business Excluding R&D 2021 2022 2023
Slide 11: Manufacturing Volumes Meet Expectations and Generate Cash Flow
Advancing medicines. Solving problems. Improving lives. 11 Manufacturing Volumes Meet Expectations and Generate Cash Flow 36,413 42,182 47,041 41,097 36,863 33,458 47,954 46,241 45,328 - 10,000 20,000 30,000 40,000 50,000 60,000 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023
Slide 12: 2024 Outlook as of March 5, 2024
Advancing medicines. Solving problems. Improving lives. 2024 Outlook as of March 5, 2024 2024 Outlook • Total revenues of approximately $48 to $51 million • Non-GAAP adjusted EBITDA loss of approximately $22 to $26 million 12
Slide 13: Thank You
Advancing medicines. Solving problems. Improving lives. Thank You
Aquestive Therapeutics — Q4 2023 Earnings Presentation on 6ix